WallStSmart

Leidos Holdings Inc (LDOS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Leidos Holdings Inc generates 6534% more annual revenue ($17.17B vs $258.90M). LDOS leads profitability with a 8.4% profit margin vs -15.5%. LDOS earns a higher WallStSmart Score of 57/100 (C).

LDOS

Buy

57

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 6.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.80

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LDOSUndervalued (+2.5%)

Margin of Safety

+2.5%

Fair Value

$177.43

Current Price

$149.23

$28.20 discount

UndervaluedFair: $177.43Overvalued
ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.01

$28.81 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LDOS2 strengths · Avg: 9.0/10
Return on EquityProfitability
31.0%10/10

Every $100 of equity generates 31 in profit

P/E RatioValuation
13.4x8/10

Attractively priced relative to earnings

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

LDOS3 concerns · Avg: 3.0/10
PEG RatioValuation
2.464/10

Expensive relative to growth rate

Debt/EquityHealth
1.213/10

Elevated debt levels

Revenue GrowthGrowth
-3.6%2/10

Revenue declined 3.6%

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : LDOS

The strongest argument for LDOS centers on Return on Equity, P/E Ratio.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : LDOS

The primary concerns for LDOS are PEG Ratio, Debt/Equity, Revenue Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

LDOS profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

LDOS generates stronger free cash flow (452M), providing more financial flexibility.

Bottom Line

LDOS scores higher overall (57/100 vs 38/100). ZEPP offers better value entry with a 48.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Leidos Holdings Inc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Leidos, formerly known as Science Applications International Corporation (SAIC), is an American defense, aviation, information technology (Lockheed Martin IS&GS), and biomedical research company headquartered in Reston, Virginia, that provides scientific, engineering, systems integration, and technical services.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?